4527 On Other Exchanges
4527 is not on other exchanges.

rohto pharmaceutical co ltd (4527) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROHTO PHARMACEUTICAL CO LTD (4527)

Related News

No related news articles were found.

rohto pharmaceutical co ltd (4527) Related Businessweek News

No Related Businessweek News Found

rohto pharmaceutical co ltd (4527) Details

Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. It offers eye care products, such as eye drops, care for contact lenses, and eye wash; facial care products comprising face wash, lotions, and creams; medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, Chinese herbal medicines, and supplements; and non-prescription medicines. The company also operates beauty counters that provide skin care products under the episteme, Obagi, and Hada-Labo brands. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical Co., Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

6,635 Employees
Last Reported Date: 06/26/17
Founded in 1899

rohto pharmaceutical co ltd (4527) Top Compensated Officers

Chairman & CEO
Total Annual Compensation: ¥169.0M
Compensation as of Fiscal Year 2017.
rohto pharmaceutical co ltd
Rohto Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018

Rohto Pharmaceutical Co., Ltd. announced consolidated earnings results for the nine months ended December 31, 2017. For the period, the company reported net sales of JPY 124,109 million against JPY 111,422 million a year ago. Operating income was JPY 15,607 million against JPY 12,392 million a year ago. Ordinary income was JPY 15,753 million against JPY 12,966 million a year ago. Profit attributable to owners of parent was JPY 10,102 million against JPY 8,414 million a year ago. Diluted net income per share was JPY 88.31 against JPY 73.62 a year ago. Profit before income taxes was JPY 15,212 million against JPY 12,216 million a year ago. For the fiscal year ending March 31, 2018, the company expects consolidated net sales of JPY 165,000 million, operating income of JPY million, ordinary income of JPY 16,900 million and profit attributable to owners of parent of JPY 10,500 million or JPY 92.17 per share.

Rohto Pharmaceutical Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2018

Rohto Pharmaceutical Co., Ltd. provided year-end dividend guidance for the fiscal year ending March 31, 2018. For the year, the company expects to pay year-end dividend of JPY 11.00 per share against JPY 11.00 per share paid for the same period a year ago.

Rohto Pharmaceutical Co., Ltd. to Report Q3, 2018 Results on Feb 09, 2018

Rohto Pharmaceutical Co., Ltd. announced that they will report Q3, 2018 results on Feb 09, 2018


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4527 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4527.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4527 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ROHTO PHARMACEUTICAL CO LTD, please visit www.rohto.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.